-
Wnt Agonist 1: A Causal Test for Wnt–GPX4
2026-08-18
Wnt agonist 1 (BML-284) provides a controlled way to test how canonical Wnt signaling influences transcription, differentiation, and redox phenotypes. This article develops an assay strategy that connects TCF activity with the Wnt/NR2F2/GPX4 chemoresistance axis while distinguishing established evidence from testable research hypotheses.
-
CCG-1423 RhoA Inhibitor Workflow Guide
2026-08-18
CCG-1423 is a pathway-level RhoA inhibitor for separating MRTF-A nuclear signaling from actin-dependent cytoskeletal effects. This guide shows how to apply it in cancer research, build mechanistic controls, and cautiously extend the workflow to RhoA/ROCK-dependent barrier and viral-entry models.
-
AG-490 for JAK2/STAT6 Macrophage Studies
2026-08-17
Use AG-490 as a pharmacological probe to test whether hepatoma-derived exosomes drive macrophage polarization through JAK2-linked signaling. This workflow combines dose-aware pathway inhibition, exosome quality controls, phosphoprotein analysis, and functional validation for more defensible cancer research results.
-
AZD3463 Workflow for ALK/IGF1R Inhibition
2026-08-17
AZD3463 combines ALK and IGF1R pathway coverage with practical workflows for neuroblastoma signaling, apoptosis, autophagy, and combination studies. This guide connects dose-response design, mutant ALK models, pathway validation, and troubleshooting to reproducible bench execution.
-
JSH-23: Reliable NF-κB Assay Design
2026-08-16
JSH-23 (SKU B1645) is a small-molecule NF-κB inhibitor for dissecting p65 nuclear localization, inflammatory transcription, and cytokine responses in cell and animal models. This scenario-based guide explains solvent handling, dose selection, controls, interpretation, and vendor evaluation for more defensible inflammation research.
-
Clarithromycin CYP3A Assay Workflow
2026-08-15
Build more interpretable CYP3A inhibition experiments with Clarithromycin, from solvent handling and concentration-response design to pathway-specific controls. The workflow links statin metabolism interaction and anticoagulant pharmacology questions without confusing CYP3A effects with non-CYP clearance pathways.
-
Tamoxifen: SERM Mechanisms and Research Use
2026-08-14
Tamoxifen is a selective estrogen receptor modulator used in breast cancer research and CreER-mediated gene knockout workflows. Evidence supports tissue-selective estrogen receptor activity, while mouse data show that high-dose prenatal exposure can cause developmental malformations.
-
SB 431542 Workflow for ALK5 Signaling Studies
2026-08-14
Use SB 431542 as a pathway-dissection tool to connect ALK5 activity with Smad2 phosphorylation, EMT, proliferation, and invasion. This practical workflow also shows how to distinguish mechanism-focused experiments from broader glioma and anti-tumor immunology applications.
-
Gefitinib (ZD1839) EGFR Assay Workflows
2026-08-13
Build more informative EGFR perturbation assays with Gefitinib (ZD1839), from phosphorylation kinetics and viability studies to blue-light skin-barrier models. This workflow emphasizes causal controls, calibrated exposure, and practical troubleshooting rather than treating pathway inhibition as a single endpoint.
-
Wnt Agonist 1: From Wnt Biology to Chemoresistance
2026-08-13
Wnt agonist 1 (BML-284) provides a practical pharmacological input for studying β-catenin–TCF signaling, cellular differentiation, and the Wnt/NR2F2/GPX4 axis implicated in platinum resistance in lung cancer brain metastasis.
-
IWR-1-endo Workflow for Wnt Signaling Inhibition
2026-08-12
Build reproducible Wnt/β-catenin assays with IWR-1-endo by combining controlled DMSO handling, concentration-response design, and orthogonal pathway readouts. The workflow also shows how single-nucleus study design can sharpen cell-state analysis without confusing atrial fibrillation findings with evidence for Wnt activity.
-
Cytochalasin B: Actin Dynamics and Cell Entry
2026-08-12
Cytochalasin B, also known as NSC 107658, is a reversible actin-filament perturbant used as a cytoskeletal research tool. In a peer-reviewed Drosophila S2-cell model, actin disruption reduced intracellular Spiroplasma eriocheiris, linking filament integrity to pathogen entry and intracellular infection.
-
Quercetin Blocks Ferroptosis in Wilson’s Disease
2026-08-11
A 2026 Phytomedicine study identifies ferroptosis and phospholipid remodeling as important components of Wilson’s disease–associated liver injury. Using complementary animal, cellular, lipidomic, and target-validation approaches, the researchers show that Quercetin acts through the ACSL4/LPCAT3/ALOX15 axis to reduce lipid peroxidation, oxidative stress, and mitochondrial dysfunction.
-
Phosbind Acrylamide: Practical SDS-PAGE Guide
2026-08-11
Phosbind Acrylamide is a phosphate-binding reagent for resolving phosphorylation-dependent mobility differences during SDS-PAGE without relying on phospho-specific antibodies. It is most appropriate for exploratory protein phosphorylation analysis of targets in the stated 30–130 kDa range, but it should not be treated as a phosphosite-identification, stoichiometry, or pathway-specific assay.
-
Rotigotine Hydrochloride in PD Research
2026-08-10
Rotigotine hydrochloride supports both cellular neuroprotection assays and route-sensitive Parkinson’s disease models. Its broad dopaminergic activity also enables translational studies of motor and non-motor outcomes, including lower urinary tract dysfunction.